Tiziana Life Sciences Announces $4 Million Grant Awarded by National Institutes of Health to Study Anti-CD3 in Alzheimer’s Disease

1 year ago

NEW YORK, Sept. 19, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology…

Dr. Paulo Fontoura, MD, PhD, joins STALICLA as Chief Scientific and Clinical Development Advisor

1 year ago

Press Release Dr. Paulo Fontoura, MD, PhD, joins STALICLA as Chief Scientific and Clinical Development Advisor Geneva, Switzerland – September…

BioRestorative Therapies’ IFATS 2024 Presentation to Feature ThermoStem® Platform’s Potential to Deliver a Superior Efficacy and Tolerability Profile Over GLP-1 Drugs

1 year ago

MELVILLE, N.Y., Sept. 19, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a clinical stage…

ITM to Present at Upcoming Radiopharmaceutical Investor Conferences in New York City

1 year ago

Garching / Munich, September 19, 2024 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced…

LinkGevity Awarded Deep-Tech EU Grant

1 year ago

Sisters Leading the Charge in AI-Driven Drug Discovery: Transforming the Future of Age-Related Disease TreatmentLONDON, Sept. 19, 2024 (GLOBE NEWSWIRE)…

ONWARD® Medical Announces Third Implant of Brain-Computer Interface (BCI) System to Restore Movement after Spinal Cord Injury

1 year ago

Company continues pioneering research on BCI-enabled system to restore mobility after spinal cord injuryEINDHOVEN, The Netherlands, Sept. 19, 2024 (GLOBE…

Basilea enters into agreement with BARDA to develop novel antifungals and antibacterials and receives initial funding

1 year ago

Initial funding of USD 29 million to support development of Basilea’s clinical stage first-in-class antifungals, fosmanogepix and BAL2062Multi-year Other Transaction…

U.S. grants Vidac Pharma patent offering broad protection of mode of action underlying its oncology drug candidates

1 year ago

London (UK), September 19 2024 – Vidac Pharma Holdings Plc. (Hamburg and Stuttgart: T9G; ISIN:GB00BM9XQ619; WKN: A3DTUQ), a clinical-stage oncology biopharmaceutical…

argenx Announces Publication in The Lancet Neurology of Pivotal ADHERE Study Data in Chronic Inflammatory Demyelinating Polyneuropathy

1 year ago

ADHERE was largest and most innovative clinical trial of CIDP patients to date VYVGART® Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) demonstrated…

Positive phase III results show Xofluza significantly reduces the transmission of influenza viruses

1 year ago

Data from the CENTERSTONE study shows single-dose Xofluza reduces transmission of influenza from an infected person to household membersThis is…